Certificate

Brand

Illumina

Product Type

Instrument

Highlights

Scalable platform; Flexible performance & Streamlined operation

Model: NovaSeq 6000
Manufacturer: Illumina/USA
– Scalable platform
Match data output, time to results, and price per sample to study needs
– Flexible performance
Configure sequencing method, flow cell type, and read length to support a broad range of applications
– Streamlined operation
Increase lab efficiency with a simplified workflow and reduced hands-on time

Application

– Large Whole-Genome Sequencing (human, plant, animal)
– Small Whole-Genome Sequencing (microbe, virus)
– Exome Sequencing
– Targeted Gene Sequencing (amplicon, gene panel)
– RNA sequencing
– Methylation sequencing
– Shotgun Metagenomics

Specifications

 

 Flow cell
SP S1 S2 S4
Output data 2 × 50 bp 65–80 Gb 134–167 Gb 333–417 Gb N/A
2 × 100 bp N/A 266–333 Gb 667–833 Gb 1600–2000 Gb
2 × 150 bp 200–250 Gb 400–500 Gb 1000–1250 Gb 2400–3000 Gb
Quality of Q30
2 × 50 bp ≥ 85%
2 × 100 bp ≥ 80%
2 × 150 bp ≥ 75%
Running time 2 × 50 bp ~13 hr ~13 hr ~16 hr N/A
2 × 100 bp N/A ~19 hr ~25 hr ~36 hr
2 × 150 bp ~25 hr ~25 hr ~36 hr ~44 hr

Details: https://sapac.illumina.com/systems/sequencing-platforms/novaseq.html

Other information

Supplier

Illumina

Related Products

NgeneBio – SOLIDaccuTest™

SOLIDaccuTest™ is an excellent tool for discovering variants associated with solid tumors using a comprehensive approach to next-generation sequencing (NGS). It reflects the latest research trends and is optimized for medical purposes by selecting essential genes of solid tumors including lung, colon, breast, skin brain, stomach and ovarian cancers, etc.

Solution: NgeneBio – SOLIDaccuTest™

SOLIDaccuTest™ is an excellent tool to explorer variants associated with solid tumors using a comprehensive method of next-generation sequencing (NGS). It reflects the latest research trends and is optimized for the medical purpose by selecting essential genes of solid tumors including lung, colon, breast, skin brain, gastric, ovarian cancers, etc.

 

BRCAaccuTest™ & BRCAaccuTest™PLUS

BRCAaccuTest™ PLUS with CE-IVD certificate for HBOC Breast/Ovarian Cancer Test

BRCAaccuTest™ & BRCAaccuTest™PLUS

BRCAaccuTest™ & BRCAaccuTest™PLUS is a regent for producing libraries for
analyzing the BRCA ½ genes using the NGS (next-generation sequencing) method,
which analyzes genomic DNA derived from blood or FFPE tissues.

Next-Generation Sequencing System – NextSeq 2000

 The NextSeq 2000 Sequencing System uses patterned flow cells similar to those that power the NovaSeq™ 6000 System. The result is a highly flexible and scalable benchtop system that offers the highest cluster density flow cell of any on-market NGS system to date, driving down the cost per gigabase (Gb) of the sequencing run.

NextSeq 1000 sequencing system

Product Information

Model: NextSeq 1000

Manufacturer: Illumina

Origin: Singapore/United States

Launching year: 01/2020

PANARealTyperTM HPV Kit

PANA RealTyperTM HPV Kit is a CE marked diagnostic device in accordance with the European Union in vitro Diagnostic Medical Device Directive 98/79/EC.

Next-Generation Sequencing System – NovaSeq 6000

Model: NovaSeq 6000
Manufacturer: Illumina/USA
– Scalable platform
Match data output, time to results, and price per sample to study needs
– Flexible performance
Configure sequencing method, flow cell type, and read length to support a broad range of applications
– Streamlined operation
Increase lab efficiency with a simplified workflow and reduced hands-on time

Next Generation Sequencing System – iSeq 100

Model: iSeq 100
Manufacturer: Illumina/USA
Illumina’s smallest next-generation DNA sequencing system, with small, fast and efficient sequencing throughput, suitable for all labs
– Fast data generation: Suitable for small projects, on a dedicated device, low throughput with fast turnaround times
– Convenient operation: Control the sequencing process from start to finish and ensure independent sequencing instead of outsourcing.

TruSight® Tumor 26

TruSight Tumor 26 Kit includes library preparation reagent set and uses next-generation sequencing (NGS) technology to provide a comprehensive assessment of 26 genes that are commonly related to mutations in solid tumors and somatic variants